Reconstitution with pimecrolimus cream 1% of steroid-damaged skin in adults with atopic dermatitis

Journal of Drugs in Dermatology, Jan, 2007

Sponsored by Novartis. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of steroid-damaged skin and disease control.

Condition          Intervention        Phase

Atopic Dermatitis  Drug: Pimecrolimus  Phase IV

Study ID Numbers: CASM981CDE20

ClinicalTrials.gov Identifier: NCT00367393

COPYRIGHT 2007 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2007 Gale Group

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here

Content provided in partnership with Thompson Gale